On the vaccine front, American biotech firm Moderna was one of the first companies in the world to react to the Covid-19 outbreak back in January.
Alongside the US NIH (National Institute of Health), it began working on its mRNA-1273 vaccine candidate before the first coronavirus cases outside of China had been confirmed.
This potential Covid-19 vaccine has since entered clinical trials, received a funding boost of close to $500m and been fast-tracked through regulatory protocols by the US Food and Drug Administration (FDA).
With Moderna joining Pfizer, Merck, Johnson & Johnson and AstraZeneca as the “finalists” in Donald Trump’s Operation Warp Speed last week, we take a closer look at how this relatively young biotech company moved to the forefront of the race to find a coronavirus vaccine.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData